Chemical inhibitors of SPR1 include a variety of compounds that target different signaling pathways and enzymes which are known to regulate the activity of SPR1 through phosphorylation events or other cellular mechanisms. Staurosporine is a potent protein kinase inhibitor, and its broad action can inhibit kinases that are responsible for the phosphorylation of SPR1, leading to a reduction in SPR1 activity. Similarly, Bisindolylmaleimide I targets protein kinase C, which is known to phosphorylate substrates like SPR1, thereby inhibiting SPR1's role in signal transduction. H-89, a specific inhibitor of protein kinase A, also contributes to the downregulation of SPR1 activity by preventing its phosphorylation. LY294002 and Wortmannin are inhibitors of PI3K, which is upstream of many signaling pathways that could impact the activity of SPR1, thus these inhibitors can dampen the pathways that activate SPR1.
Furthermore, PD98059 and U0126 are inhibitors of MEK, a kinase within the MAPK/ERK pathway; inhibition of this pathway is likely to decrease the phosphorylation and therefore the activity of SPR1. SB203580 takes a similar approach by targeting p38 MAP kinase, which can phosphorylate SPR1, leading to a decrease in its activity. SP600125 inhibits JNK, another kinase that can phosphorylate SPR1, thus reducing its functional activity within the cell. Rapamycin inhibits mTOR, a central regulator of cell growth and proliferation, which can indirectly affect the activity of SPR1 by modulating associated signaling networks. Y-27632 inhibits ROCK, impacting the cytoskeleton dynamics and potentially the activity of SPR1. Lastly, Gefitinib inhibits the EGFR tyrosine kinase, which is part of a pathway that governs the activation of several proteins including SPR1, and thereby could reduce the activity of SPR1 by limiting upstream signaling events. The combined action of these inhibitors on various kinases and signaling pathways provides a comprehensive approach to decrease the activity of SPR1 without affecting its expression levels.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Inhibits protein kinases that could phosphorylate SPR1, reducing its activity in signal transduction pathways. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Specifically inhibits protein kinase C which may phosphorylate SPR1, thus inhibiting its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, potentially reducing SPR1 activity by altering downstream signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK, which is part of the MAPK/ERK pathway, possibly reducing phosphorylation of SPR1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAP kinase which might phosphorylate SPR1, reducing its functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which could phosphorylate SPR1, thereby reducing its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Inhibits PI3K like LY294002, potentially reducing SPR1 activity by affecting downstream signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, which may influence SPR1 activity by altering associated signaling pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Inhibits ROCK, which could affect SPR1 activity through changes in cellular cytoskeleton dynamics. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Inhibits MEK1/2, potentially decreasing ERK1/2 signaling and reducing phosphorylation of SPR1. | ||||||